An observational study in Prodromal Schizophrenia, sponsored by Ohio State University. Enrolling by invitation at 1 site in United States. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Ohio State University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Schizotypal Personality Disorder with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Schizotypal Personality Disorder · United States.
Among the 20 studies in Schizotypal Personality Disorder with a site in United States, this one is the only one that started in 2019, is one of 2 observational ones, and was the 14th registered.
49 studies on the registry are indexed under Schizotypal Personality Disorder; 12 are open to participants now.
Browse Schizotypal Personality Disorder studies →3 of the 20 studies in Schizotypal Personality Disorder with a site in United States are open now. Recruiting first, the newest first:
Northwell Health · Sites in United States
Ages 14–20
University of Alabama at Birmingham · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Schizotypal Personality Disorder studies recruiting now, 1 sets no upper age limit and 8 stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 12 Years to 25 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 45 across the 17 interventional studies, 52 across the 2 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
Ohio State University has 1 study filed under Schizotypal Personality Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Schizotypal Personality Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04338152University of California, Los AngelesFamily-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial | 2026-12-30 |
| NCT05877716University of MinnesotaEPI-MINN: Targeting Cognition and Motivation - National | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Schizotypal Personality Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis. The purpose of this study is to evaluate the long-term outcomes among individuals participating in this clinical service.
The Ohio State University Early Psychosis Intervention Center (OSU EPICENTER) is implementing a specialized clinical program to serve individuals ages 12-25 who meet clinical high risk criteria for a psychosis (CHR-P). The purpose of this project is to evaluate (i) correlates of baseline characteristics among clinic participants; (ii) outcomes among individuals participating in this clinical service; and (iii) predictors and mediators of longitudinal outcomes among individuals participating in this clinical service.
This program evaluation will include all patients referred to The OSU EPICENTER CHR-P clinical program.
Inclusion Criteria:
Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
Time to remission of clinical-high risk status for psychosis
Using criteria inspired by Nelson et al. (2018), remission of clinical high risk status for psychosis is defined as simultaneous remission of both (i) symptoms and (ii) functional deficits associated with prodromal psychosis. Remission of symptoms is defined as all positive symptom items scored less than 3 on the Structured Clinical Interview for Prodromal States (SIPS). Each item is rated from 0-6 with higher scores indicating greater severity of symptoms. Remission of functional deficits is defined as a 5-point increase on the Personal and Social Performance scale (PSP: Morosini et al., 2000) as compared to baseline assessment or the PSP score ≥ 70. Scores range from 0-100 with higher scores indicative of better personal and social functioning.
Time frame: Remission status assessed at all treatment visits which will occur approximately once every week for up to 104 weeks
Change from baseline in quality of life assessed every six months for up to 24 months
Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF) as compared to baseline assessment The WHOQOL-BREF provides scores for four subscales of quality of life: physical health, psychological health, social relationships, and environment. Scores range from 0-100 with higher scores indicative of greater quality of life
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change in from baseline in cognitive functioning assessed every six months for up to 24 months
Change in scores on the MATRICS Consensus Cognitive Battery (MCCB) as compared to baseline assessment. The MCCB provides an overall cognitive composite score as well as subscale scores for processing speed, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem-solving, and social cognition. Scores range from 0-100 with higher scores indicative of greater cognitive functioning
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in suicidality assessed every six months for up to 24 months
Change in scores on the Columbia Suicide Severity Rating Scale (C-SSRS)as compared to baseline assessment. The C-SSRS provide two subscales: suicidal ideation and suicidal behavior. The former is an ordinal rating scale ranging from 0-6 with higher scores indicative of greater suicidal ideation. The latter is a nominal scale identifying the absence/presence of different suicidal behaviors.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in substance use severity assessed every six months for up to 24 months
Change in scores on the HABITS scale as compare to baseline as compared to baseline assessment. The HABITS assesses the frequency/amount of use of different illicit substances with higher scores indicative of greater frequency/amount. There is no predetermined possible range of scores as scores are raw values with regard to frequency/amount of use (e.g., number of cigarettes smoked per day)
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in anxiety assessed every six months for up to 24 months
Change in scores on the Hamilton Anxiety Scale scale as compared to baseline assessment.. The total score on this measure ranges from 0-56 with higher scores indicative of worse anxiety
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in depressed mood assessed every six months for up to 24 months
Change in scores on the Calgary Depression Scale for Schizophrenia as compared to baseline assessment. Total scores range from 0-3 with higher scores indicative of worse depression
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in symptomatology assessed every six months for up to 24 months
Change in scores on the Structured Interview for Psychosis Risk Syndromes as compared to baseline assessment. Item scores range from 0-6 with higher scores indicative of worse symptomatology
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in social functioning assessed every six months for up to 24 months
Change in scores on the Global Functioning: Social as compared to baseline assessment. Scores range from 1-10 with higher scores indicative of better social functioning
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in role functioning assessed every six months for up to 24 months
Change in scores on the Global Functioning: Role as compared to baseline assessment. Scores range from 1-10 with higher scores indicative of better role functioning
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in service utilization assessed every six months for up to 24 months
Change in utilization of health care and related social services as tracked using the Service Utilization and Resources Form as compared to baseline assessment.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in medication adherence assessed every six months for up to 24 months
Change in medication adherence as tracked using the Medication Adherence rating Scale as compared to baseline assessment. Scores range from 0-10 with higher scores indicative of greater adherence to prescribed medication.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in experience of trauma assessed every six months for up to 24 months
Change in experience of trauma as tracked using the Brief Trauma Questionnaire as compared to baseline assessment.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in health-related quality of life assessed every six months for up to 24 months
Change in health-related quality of life as assessed using the RAND 36-Item Health Survey as compared to baseline assessment. Scores on this measure range from 0-100 with higher scores indicative of greater health-related quality of life.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in capability for suicide/lethal self-injury assessed every six months for up to 24 months
Change in capability for suicide/lethal self-injury as assessed using the Acquired Capacity for Suicide Scale as compared to baseline assessment. Higher scores on this measure are indicative of greater capability for suicide/lethal self-injury.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in beliefs about use of alcohol assessed every six months for up to 24 months
Change in belief about use of alcohol as assessed using the Alcohol Expectancy Questionnaire as compared to baseline assessment. Higher scores on this measure are indicative of more positive beliefs about use of alcohol
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in beliefs about use of marijuana assessed every six months for up to 24 months
Change in belief about use of alcohol as assessed using the Marijuana Effect Expectancy Questionnaire as compared to baseline assessment. Higher scores on this measure are indicative of more positive beliefs about use of marijuana
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in recognition of predilection to common thinking errors assessed every six months for up to 24 months
Change in recognition of predilection to common thinking errors as assessed using the Beck Cognitive Insight Scale as compared to baseline assessment. Higher scores on this measure are indicative of greater recognition of one's predilection to common thinking errors
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in perceptions of core qualities of self and others assessed every six months for up to 24 months
Change in perception of core qualities of self and others as assessed using the Brief Core Schema Scale as compared to baseline assessment. Scores on this measure assess whether an individual maintains more positive or negative perceptions about themselves and other people
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in cognitive biases commonly experienced by individuals with psychosis assessed every six months for up to 24 months
Change in cognitive biases commonly experienced by individuals with psychosis as assessed using the Cognitive Biases Questionnaire in Psychosis as compared to baseline assessment. Scores on this measure assess whether an individual is more likely to experience cognitive biases commonly experienced by individuals with psychosis
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in executive functioning assessed every six months for up to 24 months
Change in executive functioning as assessed using the Delis-Kaplan Executive Functioning System as compared to baseline assessment. Higher scores on this measure are indicative of greater executive functioning skills.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in motor functioning assessed every six months for up to 24 months
Change in motor functioning as assessed using the Finger Tapping Test and Grooved Pegboard as compared to baseline assessment. Higher scores on these measures are indicative of greater motor functioning.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in Body Mass Index (BMI) as assessed every six months for up to 24 months
Change in BMI as compared to baseline assessment. BMI to be calculated as kg/m\^2
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in resting blood pressure as assessed every six months for up to 24 months
Change in resting blood pressure as compared to baseline assessment.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in resting pulse as assessed every six months for up to 24 months
Change in resting pulse as compared to baseline assessment.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in theory of mind assessed every six months for up to 24 months
Change in theory of mind as assessed using the Hinting Task and the Movie for the Assessment of Social Cognition as compared to baseline assessment. Higher scores on these measures are indicative of greater theory of mind.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in internalized stigma associated with a mental illness assessed every six months for up to 24 months
Change in internalized stigma as assessed using the Internalized Stigma of Mental Health Scale as compared to baseline assessment. Higher scores on this measures are indicative of greater internalized stigma.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in experienced stigma associated with a mental illness assessed every six months for up to 24 months
Change in experienced stigma as assessed using the Stigma Questionnaire as compared to baseline assessment. Higher scores on this measures are indicative of greater experience of stigma.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in level of physical activity assessed every six months for up to 24 months
Change in level of physical activity assessed using the International Physical Activity Questionnaire as compared to baseline assessment. Higher scores on this measures are indicative of greater level of physical activity.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in perceived belongingness and perceived burdensomeness assessed every six months for up to 24 months
Change in perceived belongingness and perceived burdensomeness assessed using the Interpersonal Needs Questionnaire as compared to baseline assessment. Higher scores on this measures are indicative of lower perceived belongingness and greater perceived burdensomeness.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in insight into cognitive abilities assessed every six months for up to 24 months
Change in insight into cognitive abilities assessed using the Measure of Insight into Cognition as compared to baseline assessment. Higher scores on this measures are indicative of greater insight into cognitive abilities.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in metacognition assessed every six months for up to 24 months
Change in metacognition assessed using the Metacognition Awareness Inventory and modified Zoo Task as compared to baseline assessment. Higher scores on these measures are indicative of greater metacognitive abilities.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in use of tobacco products assessed every six months for up to 24 months
Change in use of tobacco products assessed using the PATH Assessment of Tobacco Use as compared to baseline assessment. This measure track rate of use of different tobacco products
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in symptomatology associated with Post Traumatic Stress Disorder assessed every six months for up to 24 months
Change in symptomatology associated with Post Traumatic Stress Disorder assessed using the PTSD Checklist-5 as compared to baseline assessment. Higher scores on this measure are associated with greater severity of symptoms associated with PTSD
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in quality of socialization assessed every six months for up to 24 months
Change in quality of socialization assessed using the Quality of Socialization Questionnaire as compared to baseline assessment. Higher scores on this measure are associated with greater quality of socialization
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in referential thinking assessed every six months for up to 24 months
Change in referential thinking assessed using the Referential Thinking Scale as compared to baseline assessment. Higher scores on this measure are associated with greater referential thinking
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in perceptions of self, others, and personal agency assessed every six months for up to 24 months
Change in perceptions of self, others, and personal agency assessed using the Self-Descriptive Narrative and accompanying coding system as compared to baseline assessment.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in responsiveness in social interactions assessed every six months for up to 24 months
Change in responsiveness in social interactions assessed using the Social Responsiveness Scale as compared to baseline assessment. Higher scores are associated with greater responsiveness in social interactions
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in sense of causation and personal agency assessed every six months for up to 24 months
Change in sense of causation and personal agency assessed using the Tones, Action Primes, and Agency Task as compared to baseline assessment.
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in Big-5 personality traits assessed every six months for up to 24 months
Change in Big-5 personality traits assessed using the Ten-Item Personality Inventory as compared to baseline assessment. Higher scores are indicative of greater predilection to a specific Big 5 personality trait
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in treatment motivation assessed every six months for up to 24 months
Change in treatment motivation assessed using the Treatment Motivation Questionnaire as compared to baseline assessment. Higher scores are indicative of greater treatment motivation
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Change from baseline in loneliness assessed every six months for up to 24 months
Change in loneliness assessed using the UCLA Loneliness Scale as compared to baseline assessment. Higher scores are indicative of greater loneliness
Time frame: Assessed at baseline and every six months throughout the completion of the study for up to 24 months
Plan to share: No
Started Apr 2019 (actual). Primary completion is estimated for Sep 2030, 137 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2026 → Sep 2030 and completion Sep 2026 → Sep 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Schizotypal Personality Disorder →